Clinical trial NCT05551715: Virtual Eye Model System for Personalised Refractive Surgery Treatment
Official title: Virtual Eye Model System for Personalised Refractive Surgery Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Individualized Refractive Surgery
Lead sponsor: Vissum, Instituto Oftalmológico de Alicante
Sponsor class: OTHER
Collaborators: name: COSTRUZIONI STRUMENTI OFTALMICI C.S.O. SRL
name: Centro Hospitalar e Universitário de Coimbra, E.P.E.
name: Aarhus University Hospital
First posted: 2022-09-23
Enrollment: 547
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Justification: Although great strides have been made in the past to develop VEMoS software, it has not yet been validated with actual clinical data from patients who have undergone cataract or refractive surgery.

There are some fundamental questions that must be addressed to validate and update the software, such as the objective visual quality metrics that best predict the patient's post-surgical subjective vision from the predictions of the optical properties of the eye.

The VEMoS software must be adjusted for different types of inputs and eye parameters:

Corneal tomography of MS39-AXL MS39-AXL corneal tomography + biometric data from the IOL Master MS39-AXL corneal tomography + IOL Master biometric data + total aberrometry Combinations of any of the above with the optical properties of a specific IOL, etc.

Objective The main objective is to standardize the selection of parameters to personalize refractive surgery, based on the biometric data of each patient.

The objectives necessary to achieve such an ambitious goal are:

1. Redesign VEMoS software
2. Determine which biometric data, diagnostic tools, and objective and subjective metrics of visual quality are best for the selection of optimal refractive parameters for surgery
3. Optimize the combined use of biometric data, VEMoS software, and visual quality metrics Study design The proposed multicenter clinical trial is observational and prospective. There will be three arms within the clinical trial, a no-treatment arm, a refractive surgery arm, and a cataract surgery arm. Participants in the untreated arm will undergo an ophthalmic exam only once. Participants in the other two arms will undergo two ophthalmic exams, one before and one after surgery. For all participants, cataract or refractive surgery will be performed as part of routine clinical practice. Other additional tests performed are all non-invasive.

Study population Untreated eye arm patients 18 to 40 years of age. Refractive surgery arm patients who are planned and have consented to a corneal refractive procedure to gain spectacle independence.

Cataract surgery arm patients older than 50 years who are planned and have consented to cataract surgery.

Sample size The sample sizes for each arm of the clinical trial are as follows.

Untreated eye arm:

The goal is to recruit 600 eyes from 300 patients, 100 patients in each of these groups:

Myopia (from -10 D to -0.75 D) Emmetropia (from -0.5 D to + 0.5 D) Hyperopia (from 0.75 D to 5 D)

Refractive surgery arm:

For LASIK, the goal is to recruit 800 eyes from 400 patients, 100 patients in each of these groups:

High myopia (from -10 D to -6 D) Medium myopia (from -6 D to -3 D) Low myopia (from -3 D to -1 D) Hyperopia (from +1 D to +4 D)

For SMILE, the goal is to recruit 400 eyes from 200 patients, 100 patients in each of these groups:

High myopia (from -10 D to -6 D) Average myopia (from -6 D to -3 D)

For the cataract surgery arm:

The goal is to recruit 400 eyes from 200 patients, 100 patients in each of these groups Zeiss monofocal IOLs multifocal IOL

A total of 500 patients are expected between the Vissum, IMO and IOA clinics in Miranza.

A total of 250 patients are expected between hospital and university of Coimbra epe (Portugal).

A total of 350 patients are expected at Aarhus universitetshospital (Denmark).


Eligibility criteria: Inclusion Criteria:

For the untreated eyes arm, the inclusion criterion is:

• patients from 18 to 40 years of age and with less than 2 D of astigmatism.

For the refractive surgery arm, the inclusion criteria are:

* for LASIK: sphere between -10 D and +4 D and with less than 3 D of astigmatism.
* for SMILE: sphere between -10 D and -3 D, with less than 3 D of astigmatism.

For the cataract surgery arm, the inclusion criterion is:

• patients older than 50 years old without any active ocular pathologies affecting visual capabilities except cataract and with less than 1 D of astigmatism.

Exclusion Criteria:

For the untreated eyes and the refractive surgery arms, the exclusion criteria are:

* ocular pathology affecting visual capabilities,
* reduced transparency of ocular media,
* systemic disease affecting visual capabilities.

For the cataract surgery arms, the exclusion criterion is:

* Systemic disease affecting visual capabilities.
* Ocular pathology affecting visual capabilities other than cataract
* Included patients will be excluded if surgical complications occurs

Primary outcomes:
measure: Variables to run the VEMoS software and obtain estimates and simulations Corneal Topography
timeFrame: 3 months
measure: Variables to run the VEMoS software and obtain estimates and simulations Pupil size
timeFrame: 3 months
measure: Variables to run the VEMoS software and obtain estimates and simulations anterior chamber depth
timeFrame: 3 months
measure: Variables to run the VEMoS software and obtain estimates and simulations, crystalline lens thickness
timeFrame: 3 months
measure: Variables to run the VEMoS software and obtain estimates and simulations, axial length
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alicante
country: Spain
facility: Alicante Vissum Miranza
Study officials:
References: